{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:43:14Z","timestamp":1786653794015,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Beh\u00e7et\u2019s disease is a chronic inflammatory condition that affects multiple organs and systems. It is characterized by recurrent oral and genital ulcers. A previous study reported that the IL-17A inhibitor secukinumab can improve the skin and mucosal manifestations in patients with refractory Beh\u00e7et\u2019s disease. Additionally, secukinumab has been shown to effectively improve neurological symptoms when administered for Beh\u00e7et\u2019s disease. However, we report a case where Beh\u00e7et\u2019s disease occurred after the treatment of psoriasis with the IL-17A inhibitor ixekizumab. To summarize its clinical characteristics and treatment experience, we consulted relevant domestic and international literature and conducted a literature review. We concluded that anti-IL-17A treatment may lead to the development of Beh\u00e7et\u2019s disease. The reported cases are more likely to occur in middle-aged men with varying onset times. The main manifestations include oral and vulvar mucosal ulcers. Furthermore, the gut microbiota may be involved in paradoxical Beh\u00e7et\u2019s disease.<\/jats:p>","DOI":"10.4103\/ijd.ijd_719_24","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T02:00:24Z","timestamp":1735610424000},"page":"42-46","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Paradoxical Beh\u00e7et\u2019s Disease after Ixekizumab: A Case Report and Literature Review"],"prefix":"10.4103","volume":"70","author":[{"given":"Yue-Kang","family":"Ren","sequence":"first","affiliation":[{"name":"From the Shanxi Medical University, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Sun","sequence":"additional","affiliation":[{"name":"From the Shanxi Medical University, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Ye","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ping","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"R1-20250328","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaci.2004.10.019","article-title":"IL-17 cytokine family","volume":"114","author":"Kawaguchi","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R2-20250328","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology:A systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical reactions:Anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others","volume":"53","author":"Puig","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"R5-20250328","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/03009742.2021.2014105","article-title":"Behcet's-like disease in a patient treated with Ixekizumab for chronic plaque psoriasis","volume":"51","author":"Chen","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"R6-20250328","doi-asserted-by":"crossref","first-page":"2235040","DOI":"10.1080\/09546634.2023.2235040","article-title":"Pyoderma gangrenosum and Beh\u00e7et's-like disease induced by secukinumab:A paradoxical drug reaction","volume":"34","author":"Avc\u0131","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"R7-20250328","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1111\/jdv.16454","article-title":"Report of two cases of Beh\u00e7et's disease developed during treatment with secukinumab","volume":"34","author":"Barrado-Sol\u00eds","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20250328","first-page":"116","article-title":"Beh\u00e7et's-like disease during secukinumab treatment:New paradoxical reaction?","volume":"19","author":"Calleja Algarra","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"R9-20250328","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1097\/MIB.0000000000001142","article-title":"Interleukin-17A inhibitor-induced Crohn's Disease\/Beh\u00e7et's disease-like lesions","volume":"23","author":"Shiga","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R10-20250328","doi-asserted-by":"crossref","first-page":"omz041","DOI":"10.1093\/omcr\/omz041","article-title":"Secukinumab induced Beh\u00e7et's syndrome:A report of two cases","volume":"2019","author":"Dincses","year":"2019","journal-title":"Oxf Med Case Rep"},{"key":"R11-20250328","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Beh\u00e7et syndrome:A 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"R12-20250328","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11926-022-01084-4","article-title":"Inhibiting IL-17A and IL-17F in rheumatic disease:Therapeutics help to elucidate disease mechanisms","volume":"24","author":"Tam","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"R13-20250328","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","article-title":"Efficacy of the anti-IL 17 secukinumab in refractory Beh\u00e7et's syndrome:A preliminary study","volume":"97","author":"Di Scala","year":"2019","journal-title":"J Autoimmun"},{"key":"R14-20250328","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1093\/rheumatology\/keac222","article-title":"Secukinumab in the treatment of parenchymal neuro-Beh\u00e7et's syndrome","volume":"61","author":"Liu","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20250328","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2133.2012.11099.x","article-title":"Psoriasis:Rationale for targeting interleukin-17","volume":"167","author":"Girolomoni","year":"2012","journal-title":"Br J Dermatol"},{"key":"R16-20250328","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"R17-20250328","first-page":"2093","article-title":"Microbiome and Beh\u00e7et's disease:A systematic review","volume":"41","author":"Joubert","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R18-20250328","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s40261-019-00849-7","article-title":"Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment","volume":"39","author":"Yeh","year":"2019","journal-title":"Clin Drug Investig"},{"key":"R19-20250328","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.3390\/ijms24054568","article-title":"Compositional alteration of gut microbiota in psoriasis treated with IL-23 and IL-17 inhibitors","volume":"24","author":"Huang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R20-20250328","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/CIRCRESAHA.120.317789","article-title":"Butyrate-rich diets improve redox status and fibrin lysis in Beh\u00e7et's syndrome","volume":"128","author":"Emmi","year":"2021","journal-title":"Circ Res"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_719_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:42:25Z","timestamp":1786650145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_719_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_719_24","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"2024-08-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}